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Abstract
Background Improvement in renal function and decrea-
ses in serum uric acid (SUA) have been reported following
prolonged high-intensity statin (HMG-CoA reductase
inhibitor) therapy. This post hoc analysis of the SAGE trial
examined the effect of intensive versus less intensive statin
therapy on renal function, safety, and laboratory parame-
ters, including SUA, in elderly coronary artery disease
(CAD) patients (65–85 years) with or without chronic
kidney disease (CKD).
Methods Patients were randomized to atorvastatin
80 mg/day or pravastatin 40 mg/day and treated for
12 months. Patients were stratified using Modification of
Diet in Renal Disease (MDRD) estimated glomerular fil-
tration rates (eGFRs) in CKD (eGFR \60 mL/min/
1.73 m2) and non-CKD populations.
Results Of the 893 patients randomized, 858 had com-
plete renal data and 418 of 858 (49 %) had CKD (99 %
Stage 3). Over 12 months, eGFR increased with atorvas-
tatin and remained stable with pravastatin (?2.38 vs.
?0.18 mL/min/1.73 m2, respectively; p\ 0.0001). MDRD
eGFR improved significantly in both CKD treatment arms;
however, the increased eGFR in patients without CKD was
significantly greater with atorvastatin (?2.08 mL/min/
1.73 m2) than with pravastatin (-1.04 mL/min/1.73 m2).
Modest reductions in SUA were observed in both treatment
arms, but a greater fall occurred with atorvastatin than with
pravastatin (-0.52 vs. -0.09 mg/dL, p\ 0.0001). Change
in SUA correlated negatively with changes in eGFR and
positively with changes in low-density lipoprotein choles-
terol. Reports of myalgia were rare (3.6 % CKD; 5.7 %
non-CKD), and there were no episodes of rhabdomyolysis.
Elevated serum alanine and aspartate transaminase to
[3 times the upper limit of normal occurred in 4.4 % of
atorvastatin- and 0.2 % of pravastatin-treated patients.
Conclusion Intensive management of dyslipidemia in
older patients with stable coronary heart disease may have
beneficial effects on renal function and SUA.
Key Points
This post hoc analysis of the SAGE trial suggests
that intensive treatment of dyslipidemia over 1 year
in older patients with stable coronary artery disease
had beneficial effects on renal function, based on
dual assessment of estimated glomerular filtration
rate and on serum uric acid.
Consistent with longer-term studies, relatively short-
term treatment of dyslipidemia with high-dose statin
(HMG-CoA reductase inhibitor) therapy appears to
preserve renal function and slow progression of
chronic kidney disease in a high-risk population of
older patients.
For the SAGE Investigators.
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1 Introduction
For nearly 100 years, dyslipidemia has been implicated as
a cause or a contributing factor to renal injury [1]. Analyses
of multiple clinical trials [2–9] and meta-analyses [1, 10–
12] have suggested that, in addition to preventing and/or
reducing cardiovascular events and mortality, intensive
treatment of dyslipidemia with statins (HMG-CoA reduc-
tase inhibitors) may stabilize or improve renal function in
patients with vascular disease, with or without pre-existing
renal impairment. More specifically, stabilization or
improvement in the estimated glomerular filtration rate
(eGFR) has been observed in post hoc analyses across a
broad range of patients with coronary heart disease (CHD)
or vascular disease with or without chronic kidney disease
(CKD) [2, 4–6], and in patients with CHD with or without
prior stroke [13].
Several reports have demonstrated that high-intensity statin
therapy may have additional renoprotective effects in patients
with cardiovascular disease, as statins have been shown to
stabilize or preserve renal function, reduce the quantity of
albuminuria and proteinuria, and reduce the occurrence of
contrast-induced acute kidney injury [9, 14–16], without
increasing serious renal-related adverse events (AEs) [17].
It has long been recognized that renal function declines
with aging [18–21], and the prevalence of CKD is higher in
older individuals [21, 22]. Analyses of large epidemiologic
databases and clinical studies have indicated that at least
44 % of subjects aged 65 years and older have CKD [21,
22]; the prevalence being highest for those patients aged
C80 years and for those older subjects with co-morbidities
[21]. Importantly, declines in eGFR and worsening of CKD
status have also been reported in these older cohorts of
subjects [21]. A recent meta-analysis from the CKD
Prognosis Consortium demonstrated that mortality and the
risk of end-stage renal disease increase with a 10 % or
greater reduction in eGFR over a 2-year period [23].
Few clinical trials have examined the safety or impact of
intensive statin therapy on renal function in an older high-risk
cohort with established CHD and vascular disease. This post
hoc analysis of the SAGE (Study Assessing Goals in the
Elderly) trial was designed to examine the effect of statin
therapy with atorvastatin 80 mg/day or pravastatin 40 mg/day
on renal function and laboratory parameters, including chan-
ges in serum uric acid (SUA), in an older population with
symptomatic CHD over 12 months of treatment.
2 Methods
The design of the SAGE trial, including eligibility criteria,
has been described fully elsewhere [24, 25]. The SAGE
trial was conducted in compliance with the ethical
principles originating from the Declaration of Helsinki
(Revised South Africa, 1996) and in compliance with the
institutional review board/independent ethics committee,
informed consent regulations, and International Confer-
ence on Harmonisation (ICH) Good Clinical Practice
(GCP) guidelines. Participants were aged 65–85 years
with a documented history of clinically stable coronary
artery disease (CAD) and one or more episodes of
myocardial ischemia with a total ischemia duration
C3 min during 48-h ambulatory ECG at screening, and
with baseline low-density lipoprotein cholesterol (LDL-
C) 100–250 mg/dL [24, 25]. Patients who satisfied all
recruitment criteria were randomized (double-blind) to
atorvastatin 80 mg/day or pravastatin 40 mg/day for
12 months, with 48-h ambulatory ECG at 3 and
12 months after randomization [24, 25].
Serum creatinine was measured at baseline and
Month 12 from an eGFR and was analyzed at a central
laboratory using a modified Jaffe´ alkaline picrate method
using a Roche 747 analyzer [26]. The 4-component Mod-
ification of Diet in Renal Disease (MDRD) equation was
used to calculate an eGFR based on serum creatinine [27].
MDRD was the recommended established standard used
for assessment of eGFR at the time the study was con-
ducted, in line with US National Kidney Foundation
guidelines [28].
For the present analysis, the Kidney Disease Outcomes
Quality Initiative (KDOQI) criteria for the classification
and stratification of kidney disease [28, 29] were used and
patients with an eGFR \60 mL/min/1.73 m2 at baseline
were classified as having CKD. CKD was subcategorized
according to KDOQI 2012 guidelines [29] as follows:
Stage 3a = eGFR 45–59 mL/min/1.73 m2; Stage 3b =
30–44 mL/min/1.73 m2; Stage 4 = 15–29 mL/min/1.73 m2;
and Stage 5 B15 mL/min/1.73 m2. No patients had Stage 5
CKD. Other biochemical parameters including SUA—
measured by enzyme colorimetry using a Roche 747 ana-
lyzer—as well as sodium and potassium levels were mea-
sured at baseline and Month 12 at a central laboratory.
Diabetes mellitus status was defined from either a history
of diabetes or a baseline blood glucose value of
[126 mg/dL.
Mean changes in eGFR between treatment groups,
overall, and by CKD status, diabetes status, and sex, were
compared in an analysis of covariance (ANCOVA) model,
using treatment, baseline eGFR, sex, and study center as
covariates. Additional analyses adjusted for the presence of
hypertension and/or diabetes at baseline to assess whether
these conditions had any impact on the primary observation
(change in eGFR over 1 year). For the analysis by sex, the
model included baseline eGFR and center as covariates. If
12-month data were unavailable, the last observation was
carried forward.
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An exploratory analysis investigated the effects of
baseline LDL-C and changes from baseline LDL-C on
treatment in models adjusted for these variables. The
patient cohort was grouped according to quartiles of
change in LDL-C values from baseline to Month 12. The
effect of LDL-C change from baseline on change in eGFR
was then evaluated by ANCOVA analysis with adjustments
for baseline eGFR, sex, center, and LDL-C quartile. In
another exploratory analysis, mean changes in SUA
between treatment groups, overall, and by CKD status,
diabetes status, and sex were compared using an ANCOVA
model with treatment and baseline SUA as covariates.
Pearson correlations were used to examine the association
between changes from baseline in eGFR with LDL-C and
with SUA, and between change in SUA and LDL-C.
Safety was monitored throughout SAGE by assess-
ment of AEs for all patients who took one or more doses
of study medication and had follow-up information [25].
The incidence of AEs relating to kidney injury was
determined through review of the AE database. We
selected from a standardized list of AE terms to evaluate
for safety outcomes consistent with the Medical Dic-
tionary for Regulatory Activities (MedDRA)/Pfizer
Narrow Renal Standardised MedDRA Query (SMQ),
including: ‘‘Renal impairment’’, ‘‘Renal disorder’’,
‘‘Renal failure’’, ‘‘Renal failure acute’’, ‘‘Nephritis’’,
‘‘Nephropathy’’, ‘‘Renal tubular disorder’’, or ‘‘Renal
tubular necrosis’’.
3 Results
This post hoc analysis of SAGE consisted of 858 partici-
pants who had both baseline and Month 12 eGFR mea-
surements (Fig. 1). Thirty-five SAGE patients were
excluded from the renal cohort due to incomplete data; the
majority of discontinuations were due to AEs (n = 18,
including five deaths [atorvastatin n = 1, pravastatin
n = 4]) or due to non-compliance (n = 7) (see Fig. 1). The
mean (±standard deviation) age of the renal cohort was
72.4 ± 5.1 years, with 262 patients (30.5 %) aged
[75 years. At baseline 49 % of the participants had CKD
(eGFR B60 mL/min/1.73 m2), with 99 % (415/418) clas-
sified as Stage 3 (eGFR 30–60 mL/min/1.73 m2)
(Table 1). The majority of patients with Stage 3 CKD were
categorized as Stage 3a (84 %), according to KDOQI cri-
teria [29].
Baseline triglycerides and total cholesterol were higher
in patients with versus without CKD (Table 1), but lipids
were similar across treatment arms within each CKD or
non-CKD cohort. Across all patients in this renal cohort
(both those with and without CKD), treatment with ator-
vastatin resulted in significantly greater decreases in
total cholesterol (-40.9 vs. -21.7 %), LDL-C (-56.1 vs.
-32.0 %), and triglycerides (-28.5 vs. -9.2 %) than did
pravastatin after 3 months of follow-up (p\ 0.001).
There were no significant differences in baseline eGFR
between the treatment groups, or within treatment for
patients with or without CKD (Table 1). Overall, eGFR
increased over 12 months with atorvastatin (?2.38 mL/
min/1.73 m2) and remained stable with pravastatin
(?0.18 mL/min/1.73 m2) (Fig. 2; treatment difference
p\ 0.0001). In patients with CKD, eGFR improved in
both treatment arms (atorvastatin: ?2.8 mL/min/1.73 m2;
pravastatin: ?2.3 mL/min/1.73 m2) (treatment difference
p = 0.474). In patients without CKD, a significant increase
in eGFR from baseline was observed with atorvastatin
(?2.08 mL/min/1.73 m2; p = 0.009) but not with prava-
statin (-1.04 mL/min/1.73 m2; p = 0.196) (treatment dif-
ference p = 0.0003) (Fig. 2).
Increases in eGFR were seen with both treatments when
analyzed by diabetes status; however, the difference
between statin treatments was significant only in patients
without diabetes (Table 2). The overall increase in eGFR
was significantly greater among males than females
(p = 0.003). A significant treatment effect with atorva-
statin versus pravastatin was observed in males only
(Table 2). No notable differences in the primary assess-
ment (change in eGFR) were noted for patients with or
without CKD when data were adjusted for baseline
hypertension or diabetes status in addition to baseline
eGFR and sex (data not shown).
There was a weak but significant correlation between
change in eGFR and change in LDL-C (r = -0.11;
p = 0.002). Increases in eGFR were significantly greater in
Fig. 1 Patient enrollment in the SAGE trial and inclusion in the renal
analysis cohort. *Includes two patients with cardiac events. CKD
chronic kidney disease, eGFR estimated glomerular filtration rate
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the patients with greater reductions in LDL-C (p for
trend = 0.049) (Fig. 3). After adjustment for baseline
LDL-C or change in LDL-C, the treatment effect on eGFR
remained significant.
Baseline SUA values were within a normal range in both
treatment groups, and with treatment a significantly greater
reduction in mean SUA was seen with atorvastatin than
with pravastatin treatment (p\ 0.0001). These findings
Fig. 2 Changes in estimated
glomerular filtration rate
(eGFR) from baseline (least
square mean ± standard error)
following 12 months’ treatment
with atorvastatin 80 mg/day or
pravastatin 40 mg/day in all
patients in the SAGE renal
cohort and according to chronic
kidney disease status. LDL-
C low-density lipoprotein
cholesterol
Table 2 Baseline estimated glomerular filtration rate (eGFR) and changes in eGFR following 12 months’ treatment with atorvastatin 80 mg/day
or pravastatin 40 mg/day according to diabetes mellitus status and sex
eGFR Patients with diabetesa Patients without diabetes Males Females
Atorvastatin
(n = 105)
Pravastatin
(n = 119)
Atorvastatin
(n = 328)
Pravastatin
(n = 306)
Atorvastatin
(n = 299)
Pravastatin
(n = 296)
Atorvastatin
(n = 134)
Pravastatin
(n = 129)
Baseline eGFRb
(mL/min/1.73 m2)
61.8 ± 13.1 60.4 ± 12.8 61.3 ± 11.5 61.7 ± 11.4 64.0 ± 11.6 63.3 ± 11.3 55.6 ± 10.4 56.7 ± 11.5
Change in eGFRc
(mL/min/1.73 m2)
2.2 ± 1.0 0.7 ± 1.0 2.2 ± 0.5 0.2 ± 0.5 3.7 ± 0.6 1.1 ± 0.5 0.6 ± 0.8 -0.1 ± 0.8
p valued 0.3065 0.0014 0.0001 0.4969
a Medical history of diabetes or baseline glucose[126 mg/dL
b Mean ± standard deviation
c Least square mean ± standard error
d All p values are for treatment effect of atorvastatin vs. pravastatin
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were similar when analyzed by CKD status, diabetes status,
and sex (Table 3). There was a significant (negative) cor-
relation between the change in SUA and the change in
eGFR, regardless of CKD status (CKD patients, r = -
0.373; p\ 0.0001; non-CKD patients, r = -0.344;
p\ 0.0001). There was also a positive correlation between
the change in LDL-C versus change in SUA, regardless of
CKD status (CKD patients, r = 0.181; p = 0.0002; non-
CKD patients, r = 0.262; p\ 0.0001).
Serum alanine transaminase (ALT) and aspartate
transaminase (AST) levels C3 times the upper limit of
normal were reported in 19 atorvastatin patients (11/214
[5.1 %] with CKD; 8/232 [3.4 %] without CKD) and one
pravastatin patient without CKD (1/227 [0.4 %]). There
were no persistent elevations in liver enzymes (AST,
ALT), as levels returned to normal for all patients who
were followed up for a repeat test, including for the one
pravastatin patient who permanently discontinued study
medication (not due to liver function abnormality).
Myalgia was the most common muscle-related AE,
which occurred in 25 patients without CKD (20 ator-
vastatin; five pravastatin) and 15 patients with CKD
(three atorvastatin; 12 pravastatin). Myalgia led to
discontinuation of six CKD (one atorvastatin; five pravas-
tatin) and seven non-CKD (seven atorvastatin) patients.
Myopathy was reported in one CKD patient receiving
atorvastatin. Rhabdomyolysis was not reported.
Twenty-six deaths were reported in the overall renal
cohort during the study, with more deaths recorded for
patients with CKD (n = 15 [3.48 %]) than without CKD
at baseline (n = 11 [2.40 %]). A greater number of car-
diovascular deaths were recorded in the CKD population
(n = 12) than in the non-CKD population (n = 3). A
higher number of deaths were recorded in the renal cohort
in patients receiving pravastatin (n = 18) than in those
receiving atorvastatin (n = 8), for patients with and
without CKD, many of which were adjudicated as car-
diovascular deaths (pravastatin: n = 10; atorvastatin:
n = 5). Investigator-reported renal AEs were less fre-
quent in the atorvastatin (n = 1 [renal failure]) than in the
pravastatin arm (n = 5 [renal failure, n = 2; acute renal
failure, n = 1; renal impairment, n = 2]) for CKD
patients. Investigator-reported renal AEs were very
infrequent in both treatment arms for non-CKD patients
(atorvastatin: n = 0; pravastatin: n = 1 [acute renal
failure]).
Fig. 3 Changes in estimated
glomerular filtration rate
(eGFR) from baseline (least
square mean ± standard error)
following 12 months’ treatment
with atorvastatin 80 mg/day or
pravastatin 40 mg/day, grouped
by quartile ranges of changes in
low-density lipoprotein
cholesterol from baseline. CKD
chronic kidney disease, eGFR
estimated glomerular filtration
rate
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4 Discussion
This post hoc analysis of the SAGE trial demonstrated that
1 year of intensive atorvastatin therapy (80 mg/day)
improved renal function in a high-risk cardiovascular
population of older patients with stable CAD and silent
ischemia, regardless of the presence of CKD or diabetes,
while moderate therapy with pravastatin (40 mg/day) sta-
bilized renal function over the same period of follow-up.
This observation is consistent with other analyses which
demonstrate that renoprotection varies between atorvas-
tatin and other lipid-lowering agents in subjects with vas-
cular disease [30–32].
The mechanism by which statin therapy may have a
beneficial effect on renal function remains unknown, and
may differ between statin type. We noted a weak correla-
tion between increases in eGFR with atorvastatin-associ-
ated reduction in LDL-C, so that the greatest improvement
in renal function was correlated with more intense lipid
lowering. Pravastatin had a more modest effect on renal
function, possibly secondary to a smaller effect on lipid
lowering when compared with atorvastatin [25]. The sta-
bilizing effect on eGFR with pravastatin also aligned with
findings in patients with or at high-risk of CHD over fol-
low-up of nearly 5 years [4]. However, statin-associated
renoprotection may be related to other pleiotropic effects,
and not directly related to lipid lowering. In agreement, in a
recent analysis of the prospective evaluation of proteinuria
and renal function in diabetic patients with progressive
renal disease (PLANET) I and II trials, high-dose ator-
vastatin (80 mg) was deemed to be more renoprotective
over a 1-year treatment period than high-dose rosuvastatin
(40 mg), despite rosuvastatin lowering plasma lipid con-
centrations to a greater extent than atorvastatin 80 mg in
both CKD patients with end-stage renal disease and dia-
betes [33]. Furthermore, in a post hoc analysis of statin
type, atorvastatin 80 mg lowered the urine protein:crea-
tinine ratio significantly more than both low- and high-dose
rosuvastatin in these patients [33].
The hypothesis that different statins have different renal
protective effects is further supported by both non-clinical
and clinical observations [34–43]. Statins have been
observed to modify endothelial cell and vascular physiol-
ogy in animal models [36] and show anti-inflammatory
properties [37], both of which could have renoprotective
effects. We report that in patients with CKD, eGFR
improved with atorvastatin or pravastatin, while in those
without CKD, eGFR improved in atorvastatin-treated
patients but was only stabilized with pravastatin treatment.
This suggests that the renoprotective effects of statins are
Table 3 Baseline serum uric
acid (SUA) and changes
following 12 months treatment
with atorvastatin 80 mg/day or
pravastatin 40 mg/day
according to chronic kidney
disease (CKD) status, diabetes
mellitus status, and sex
Atorvastatin Pravastatin Atorvastatin Pravastatin
All patients
n 433 425
Baseline SUAa (mg/dL) 6.30 ± 1.34 6.15 ± 1.36
Change in SUAb (mg/dL) -0.52 ± 0.04 -0.09 ± 0.04
p valuec \0.0001
Patients without CKD Patients with CKD
n 227 213 206 212
Baseline SUAa (mg/dL) 5.92 ± 1.14 5.92 ± 1.32 6.71 ± 1.41 6.39 ± 1.35
Change in SUAb (mg/dL) -0.43 ± 0.05 -0.02 ± 0.06 -0.61 ± 0.07 -0.18 ± 0.07
p valuec \0.0001 \0.0001
Patients without diabetes Patients with diabetes
n 328 306 105 119
Baseline SUAa (mg/dL) 6.33 ± 1.32 6.15 ± 1.33 6.19 ± 1.40 6.15 ± 1.43
Change in SUAb (mg/dL) -0.52 ± 0.05 -0.085 ± 0.05 -0.54 ± 0.09 -0.10 ± 0.09
p valuec \0.0001 \0.0001
Males Females
n 299 296 134 129
Baseline SUAa (mg/dL) 6.40 ± 1.31 6.40 ± 1.27 6.07 ± 1.37 5.59 ± 1.38
Change in SUAb (mg/dL) -0.55 ± 0.05 -0.14 ± 0.05 -0.48 ± 0.09 0.03 ± 0.09
p valuec \0.0001 \0.0001
a Mean ± standard deviation
b Least square mean ± standard error
c All p values are for treatment effect of atorvastatin vs. pravastatin
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more prominent in CKD patients than in non-CKD
patients. The reasons underlying these differences are
unclear; however, a number of differences in cellular
physiology are known between CKD and non-CKD
patients that could affect the outcomes observed herein
[38–43]. For example, patients with CKD have been
reported to have higher levels of inflammatory markers,
such as C-reactive protein, interleukin-1b, and tumor
necrosis factor-a, than an age-matched control population
with normal renal function [38]. Treatment with atorvas-
tatin can significantly lower these inflammatory markers in
patients with CKD; furthermore, atorvastatin treatment
may improve endothelial function and stabilize plaque-
limiting atheroembolic renal disease [38, 39]. However,
other statins may not have the same effect. In certain
populations, evidence suggests that statins may influence
blood flow [34, 35, 40–43], and this potential effect may
contribute to changes in eGFR. However, the literature is
somewhat conflicting regarding any effect, with some
studies indicating that statins increase blood flow, but only
in patients with normal endothelial function [43], whereas
other studies suggest no change in healthy subjects [41],
patients with hypercholesterolemia [40] or patients with
peripheral arterial disease [42]. Given the diversity of
populations studied, the small number of patients in the
trials, and the known influence of patient characteristics
(including CKD) and other risk factors on hemodynamics
and endothelial function (as discussed earlier), further
study is needed to clarify any statin-mediated influence on
blood flow in CKD and non-CKD patient populations.
CKD progresses rapidly in patients with coexisting
CHD, and this rapid progression leads to an increased risk
of cardiovascular events [11, 15, 44, 45]. In our 12-month
study of patients aged 65–85 years, the increase in eGFR
observed with intensive atorvastatin therapy was in
accordance with the renal benefits reported for the same
regimen in longer trials of younger CHD populations [5, 6].
In addition, the improvement in renal function among
patients with diabetes and/or CKD following intensive
atorvastatin therapy is consistent with that reported in other
post hoc analyses of atorvastatin treatment regimens over
longer follow-up [7, 46], and including in patients with
prior stroke or transient ischemic attack, both with and
without CKD [13]. Statin-associated renoprotection was
not seen in SHARP (Study of Heart and Renal Protection)
[31, 32]. This prospective clinical study was designed to
determine the effect of a statin–ezetimide combination on
cardiovascular and renal endpoints, which included pro-
gression to end-stage renal disease, doubling of serum
creatinine, and death, in patients with advanced CKD [31].
An exploratory SHARP renal analysis failed to show any
benefit from a 1 mmol/L reduction in LDL-C on slowing
progression of kidney disease in a wide variety of patients
with CKD [32]. There are important differences between
the patients studied in SHARP and our analysis of the
SAGE trial. SHARP recruited a population of patients with
well-characterized renal disease including patients with
glomerulonephritis and cystic renal disease, and excluded
subjects with prior myocardial infarction or coronary
revascularization [31]. Patients with specific renal disease
diagnoses were excluded from SAGE [25]. Another recent
analysis of the SHARP cohort demonstrated that the type
of kidney disease was a significant factor affecting pro-
gression of renal disease, as 23 % of patients with cystic
renal disease versus 10 % with glomerulonephritis and
12 % with diabetic nephropathy progressed to end-stage
renal disease [47]. The degrees of renal impairment dif-
fered at baseline and could be another factor that may
account for the lack of renoprotection in SHARP, as nearly
half of the patients in SHARP had an eGFR\15 mL/min/
1.73 m2 [31], while there were only three such subjects in
the SAGE renal cohort.
Guidelines now recommend statins or statin/ezetimide
for adults aged C50 years with eGFR B60 mL/min/
1.73 m2 who are not receiving long-term dialysis or for
those who have had a kidney transplant [48, 49]. Recom-
mendations for lipid-lowering therapy were justified on the
basis of the high cardiovascular risk status of patients with
coexisting CHD/CKD. Further incremental increases in
cardiovascular risk occur with aging [19] or coexisting co-
morbid conditions such as diabetes and hypertension [18,
44]. Despite recognized evidence for the benefits of statin
therapy in younger patients with coexisting CHD and CKD
[1], data surrounding the benefits of statin therapy for older
patients with these co-morbidities are less clear. Our data
demonstrate that an intensive atorvastatin-based treatment
regimen can stabilize or improve renal function in a high-
risk population of older patients with stable CAD and silent
ischemia, with or without CKD, and that renoprotection
was evident after 1 year. Overall, atorvastatin was more
effective than pravastatin in stabilizing or improving renal
function; however, significant improvement in renal func-
tion was also observed with pravastatin in this cohort of
patients with CKD.
The renal benefits seen with atorvastatin in SAGE are
consistent with those reported in other trials that have
examined the effect of atorvastatin on renal function [2, 5–
7, 13, 33, 46]. Although older subjects with CKD are less
likely than younger populations to progress to end-stage
renal disease, attempts should be made to modify risk
factors and stabilize renal function. Hemmelgarn and col-
leagues [18] examined the changes in renal function that
occurred in a cohort of 10,184 subjects aged 66 years or
older over a 2-year period. Absolute reductions in eGFR in
the cohort of 3191 subjects with baseline eGFR between 30
and 59 mL/min/1.73 m2 were 5.1 and 7.2 mL/min/1.73 m2
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in female and male patients, respectively, with CKD and
co-morbid diabetes, compared with 2.0 and 3.5 mL/min/
1.73 m2 for female and male CKD patients, respectively,
without diabetes [18]. The current analysis suggests that
lipid-lowering therapy may be an effective strategy for
limiting the expected decline in renal function in older
CHD subjects with CKD and with or without coexisting
diabetes.
Improvements in renal function following intensive
atorvastatin treatment are further supported by dual
assessment of change in eGFR alongside SUA. The
observed small (-0.52 mg/dL) but statistically significant
decrease in SUA with atorvastatin was also in agreement
with those reported from CHD patients aged up to 75 years
treated with atorvastatin (10–80 mg/day) [2]. The greater
fall in SUA observed with atorvastatin treatment could be
secondary to improved filtration, whereas only a stabilizing
effect was observed with pravastatin treatment. A signifi-
cant negative correlation was noted between the change in
SUA and change in eGFR; thus, as eGFR improved, SUA
fell. SUA has been reported as an independent risk factor
for cardiovascular mortality, with risk increasing as SUA
increases, even within the normal range [22, 50]. Although
improvements in the glomerular filtration rate may account
for the modest reduction in SUA, the exact mechanisms
whereby atorvastatin and pravastatin lower SUA remain to
be determined. In addition, given that the reduction in SUA
was small, although statistically significant, over the 1-year
study period, the clinical relevance of this observation
needs to be confirmed.
In the entire SAGE population [25] and in this renal
cohort, both atorvastatin 80 mg/day and pravastatin
40 mg/day were generally well-tolerated, and the AEs
recorded were as expected in a cohort of older patients
[51]. The current analysis also demonstrated that in this
cohort of older CHD patients with CKD, there did not
appear to be a greater risk of muscle-related AEs than in
those without CKD. This is in line with a recently pub-
lished analysis including 149,882 patient-years of follow-
up that failed to show any increase in renal-related serious
AEs with statins compared with controls [17]. Thus,
although safety perceptions have been cited as a reason for
not prescribing statin therapy to older patients with or
without CKD [51], the findings of this study and others do
not support the view that safety risks outweigh the car-
diovascular benefits of intensive atorvastatin therapy for
this high-risk elderly population [17, 52, 53]. Current
guidelines for treating dyslipidemia in CKD acknowledge
the potential benefits of high-dose statins in patients with
diabetes and mild-to-moderate CKD (Stages 1–3); how-
ever, dose modification is also recommended for some
statins and certain other lipid-lowering medicines in mod-
erate-to-advanced CKD (Stages 3–5) [29].
4.1 Limitations
This post hoc analysis of a randomized controlled
prospective study comparing two treatment regimens has
some limitations. CKD staging was based on eGFR
because data on proteinuria were not available, and albu-
minuria data were not analyzed. There was no placebo arm
for comparison, and patient numbers were relatively small.
There were more male than female patients in the non-
CKD cohort (83 % male); eGFR is known to differ by sex,
and the Cockroft-Gault equation is adjusted accordingly. In
addition, observations have been published suggesting that
SUA is higher in male than in female subjects both in the
general population [22] and in subjects (mean age
61 years) with CKD [54]. Although our analyses were
adjusted for sex and baseline eGFR, the uneven male:fe-
male ratio may have influenced the observations from the
non-CKD analyses. The findings of this analysis should,
therefore, be interpreted accordingly. Nevertheless, the
results were in accordance with longer analyses and similar
trials of younger patient groups [2, 5–7, 13, 33, 46].
Finally, although a number of our observations were sta-
tistically significant, the clinical relevance in a larger
patient sample cannot be inferred.
5 Conclusions
This post hoc analysis of the SAGE trial extended the
observation of renal benefits with statins to a high-risk
population of older patients with a history of stable CAD
with silent ischemia, and in particular to those with co-
existent CKD. These findings suggest that relatively short-
term (1 year), intensive management of dyslipidemia in
older patients with stable CAD might be associated with
preservation of renal function and slowed CKD progression
without increasing the risk of muscle symptoms or other
renal AEs.
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